Abstract |
The purpose of this study was to evaluate the efficacy of taxane regimens in patients with metastatic angiosarcoma. Forty-one patients with metastatic angiosarcoma treated at the National Cancer Center Hospital between January 1982 and January 2009 were retrospectively classified into 3 groups according to the treatment type: (i) taxane (n=11), (ii) non- taxane (n=14), and (iii) best supportive care (BSC; n=16) groups. The taxane group received paclitaxel (n=6), docetaxel (n=4), or albumin-bound paclitaxel (n=1), and the non- taxane group received mainly doxorubicin-containing regimens (n=12). The differences in progression-free survival (PFS) among the 3 groups were statistically significant (P<0.001). After adjusting for prognostic factors, the taxane group had significantly longer PFS than the non- taxane (hazard ratio=0.282; 95% confidence interval=0.086-0.923; P=0.036) and BSC (hazard ratio=0.015; 95% confidence interval = 0.003-0.083; P<0.001) groups. Overall survival was also significantly longer in the taxane group than in the other groups. A taxane regimen may be more effective than a non- taxane regimen for treating patients with metastatic angiosarcoma.
|
Authors | Taizo Hirata, Kan Yonemori, Masashi Ando, Akihiro Hirakawa, Hitoshi Tsuda, Tadashi Hasegawa, Hirokazu Chuman, Kenjiro Namikawa, Naoya Yamazaki, Yasuhiro Fujiwara |
Journal | European journal of dermatology : EJD
(Eur J Dermatol)
2011 Jul-Aug
Vol. 21
Issue 4
Pg. 539-45
ISSN: 1167-1122 [Print] France |
PMID | 21697045
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents, Phytogenic
- Taxoids
- Docetaxel
- Doxorubicin
- Paclitaxel
- Ifosfamide
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents, Phytogenic
(therapeutic use)
- Docetaxel
- Doxorubicin
(therapeutic use)
- Female
- Hemangiosarcoma
(drug therapy, pathology)
- Humans
- Ifosfamide
(therapeutic use)
- Male
- Middle Aged
- Neoplasm Metastasis
- Paclitaxel
(therapeutic use)
- Prognosis
- Proportional Hazards Models
- Retrospective Studies
- Survival Rate
- Taxoids
(therapeutic use)
|